Thank you, Ms. Fuller.
I'm going to stay with you, if that's okay. In written submissions to the committee, some stakeholders have expressed concern that the implementation of the amendments to the patented medicines regulations and the PMPRB guidelines will result in fewer innovative medicines being launched here in Canada. Nineteen pharmaceutical companies have further suggested that the PMPRB guidelines are complex and confusing, which is leading to uncertainty in their decision-making.
As a stakeholder, what steps has the PMPRB taken to ensure that its guidelines can be clearly understood by stakeholders and, for that matter, by the general public?